SLS Invest and SEB sell Sanos
SLS Invest and SEB have sold their stakes in Danish biotech company Sanos Bioscience A/S to Nordic Bioscience A/S.
The investors acquired a stake in the company following a DKK 60m investment in 2004, with SLS Invest becoming the largest shareholder. Sanos was established in 2004 as a spinout from Nordic Bioscience and focuses on the development of GLP-2 for the treatment of osteoporosis.
According to SLS Invest, the company has struggled to attract sufficient capital to take Sanos' osteoporosis drug through phase 3 clinical development. The sale gives Sanos the resources and capital necessary to complete the final phase 3 trials and bring the drug to market.
More on Nordics
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
Trind VC plans up to five early-stage investments in next six months
VC has deployed around 10% of its second, EUR 55m fund and plans to invest in up to 40 startups
Letter from the editor: Unquote is moving to Mergermarket
Unquote Editor Harriet Matthews outlines Unquote.com's upcoming move to the Mergermarket platform and the new capabilities and intelligence that this brings to Unquote readers
Main Capital’s Assessio to be sold to Pollen Street
Recruitment software company tripled in revenue under Main Capital’s ownership
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater